The first patient has been dosed in a small study testing SGT-212, a gene therapy candidate being developed by Solid Biosciences for people with Friedreich’s ataxia (FA). The dose-finding Phase 1b FALCON trial (NCT07180355) — a first-in-human study being conducted at two sites in the U.S. —…
